Pacira BioSciences, Inc. (PCRX)


Stock Price Forecast

April 24, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Pacira BioSciences, Inc. chart...

About the Company

We do not have any company description for Pacira BioSciences, Inc. at the moment.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

778

Exchange

Nasdaq

$122M

Total Revenue

778

Employees

$1B

Market Capitalization

35.19

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PCRX News

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

23d ago, source:

Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd ...

Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend

14d ago, source:

During the three years that the share price fell, Pacira BioSciences' earnings per share (EPS) dropped by 36% each year. In comparison the 26% compound annual share price decline isn't as bad as the ...

Pacific Biosciences of California (PACB) Price Target Decreased by 18.15% to 9.01

8d ago, source: Hosted on MSN

The average one-year price target for Pacific Biosciences of California (NasdaqGS:PACB) has been revised to 9.01 / share.

Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc

28d ago, source:

Los Angeles, CA, March 28, 2024 (GLOBE NEWSWIRE) -- Endonovo (OTC PINK: ENDV) and its subsidiary, SofPulse, Inc., today announced they have finalized and completed the Asset Purchase Agreement (APA), ...

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

9d ago, source:

Under the terms of the research collaboration extension, Sentia and Neurocrine will continue to work together to discover novel peptide antagonists targeting CRF and advance them to development ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...